Participating Companies

Aardvark Therapeutics
Clinical stage biopharmaceutical company focused on the development and commercialization of small molecule therapeutics that activate innate homeostatic pathways for the treatment of disease. Lead product, ARD-101, is a first-in-class oral composition that is gut restricted, yet conveys systemic effects via activation of gut peptide hormone secretion. Preclinical data demonstrate safety as well as efficacy in a number of metabolic and inflammatory disease models. [more information]

Adiso Therapeutics inc
ADS024 (SS-LBP) has just completed a Phase 1b study for the prevention of recurrent CDI and will be undertaking a Phase 2 study in moderate ulcerative colitis (UC) this year. ADS051 is nearly completing enrollment in a Ph1b study in moderate-to-severe ulcerative colitis (UC). Adiso is also developing a novel dual inflammasome inhibitor (NLRP3 & NLRP1) in discovery phase which is being initially explored in respiratory inflammation, and dermal application with multiple future therapeutic areas to pursue. [more information]

Affibody
Lead candidate Izokibep, supported by partnership with Acelyrin, is an IL-17 inhibitor with multiple Ph2 programs in progress (PSO, axSpA, uveitis, HS, PsA). ACR50 primary endpoint met for 16 wk data in PsA. First patient dosed in pivotal Phase 2b trial for uveitis filed in 1H2022 with 24 wk data expected in 2023. [more information]

AgomAb Therapeutics
Capitalizing on a deep understanding of growth factor biology, Agomab has built a pipeline of product candidates that address well-validated and potentially disease-modifying targets: Transforming Growth Factor Beta (TGF-β) through inhibition of its intracellular receptor ALK-5 and Hepatocyte Growth Factor (HGF) through agonism of its receptor MET. The company’s lead drug candidate, AGMB-129, is a gastrointestinal tract-restricted oral ALK-5 inhibitor in development for the treatment of fibrostenotic Crohn’s disease and is currently in final stages of a Phase 1 clinical trial. The second TGF-β targeting drug candidate, AGMB-447, is a lung-restricted ALK-5-inhibitor in development for the treatment of idiopathic pulmonary fibrosis and is currently in IND-enabling studies. [more information]

Alladapt
Developing a potentially best-in-class oral immunotherapy that addresses a broad range of food allergies. ADP101, which is in a Ph 1/2 study and an OLE study, is designed to desensitize patients allergic to one or to multiple foods simultaneously to mitigate the risk of severe, life-threatening allergic reactions. The Company was co-founded by Dr. Kari Nadeau, a renowned food allergist, and former 23andMe exec, Ashley Dombkowski who serves is CEO. Data from Ph 1/2 study expected 1Q23. [more information]

Arbor Biotechnologies
With the most extensive library of CRISPR nucleases in the industry, a deep bench of world-class founders, scientific advisors, and a leadership team with a proven track record of developing novel platforms and therapeutics, Arbor is well-positioned to develop curative genetic medicines for all patients with genetic diseases. Arbor’s pipeline is powered by its proprietary biodiscovery engine, which blends computational search and scientific expertise to discover, screen, and engineer proteins at unprecedented scale and speed. Arbor has raised more than $300 million to date and top investors include ARCH Venture Partners, Temasek, Ally Bridge Group, and TCG Crossover. [more information]

Bexion Pharmaceuticals
A clinical-stage biopharmaceutical company developing a new generation of biologic immunotherapy to treat Solid Tumor Cancers and Chemotherapy Induced Peripheral Neuropathy (CIPN). Bexion's lead asset BXQ-350 activates Sphingoloid Metabolism and has demonstrated excellent safety and monotherapy benefits across multiple tumor types in its completed adult and pediatric Ph 1 study. Ph 2 study in CRC expected 4Q22. The Company has $80M raised to date. [more information]

BrickBio
BrickBio is actively developing two lead internal candidates with oncology indications, while co-developing two candidates with large pharma partners, on which BrickBio owns 50% of the intellectual property of the resulting drug. [more information]

Caraway Therapeutics
The Company is backed by top-tier investors, including SV Health Investors, AbbVie Ventures, MRLV Fund, Amgen Ventures, Dementia Discovery Fund, Alexandria Venture Investments, and Eisai Innovation. [more information]

Catamaran Bio
Our proprietary capabilities enable us to harness the natural cancer-fighting properties of NK cells and enhance and tailor their effectiveness with the power of synthetic biology and innovative non-viral cell engineering. We are using our TAILWIND™ platform, an integrated suite of technologies, to specifically address the end-to-end methods of engineering, processing and manufacturing NK cells and rapidly advance our pipeline of CAR-NK cell therapy programs. Our team combines experienced biopharmaceutical leadership with founding scientists who are pioneers in NK cell biology, engineering, manufacturing, and clinical application. [more information]

Celsius Therapeutics
Celsius Therapeutics is a biotechnology company that develops precision medicines for cancer and autoimmune disease patients. [more information]

Cerevance
Developer of novel therapeutics intended to advance new medicines for serious neurological diseases.
[more information]

CoRegen Inc
This therapy is effective with complete and durable elimination of cancer cells, safe with no signs of toxicity, no inflammation, retaining healthy metabolism, and preventive of cancer recurrence. [more information]

DTx Pharma
The company's technology enables efficient delivery of nucleic acid drugs to tissues throughout the body, enabling healthcare providers to deliver oligos in vivo at therapeutically relevant doses that work in many cell types including neurons, endothelial and T cells. Their pipeline consists of novel therapeutic candidates to help patients with neuromuscular, muscle, and CNS diseases. DTx has raised more than $100M in combined investment from healthcare investors including RA Capital and Access Biotechnology, pharmaceutical companies such as Eli Lilly, the National Institute of Health (NIH), and research foundations such as the CMT Research Foundation (CMTRF). [more information]

Enterome
Recognizing that the Pharma industry is only beginning to understand how to potentially optimize the therapeutic benefits of T cell therapies (CART & TCRT) and with a great deal still to learn, Enterome is taking a deliberately new and different approach with its technology platform enabling each patient to benefit from a specific and major expansion of the best part of its own T cell repertoire (Effector Memory T cells), in a highly sophisticated and unprecedented way. Our OncoMimicTM technology is enabling the overcoming of immune tolerance against cancer cells with broad applicability in the high unmet need solid tumor space via an off-the-shelf, easy to manufacture technology. Our lead asset EO2401 is currently in phase 2 in recurrent Glioblastoma (rGBM) and pivotal trial in Adrenal carcinoma (ACC). [more information]

Epic Bio
Epicrispr Biotechnologies is a pre-clinical stage gene therapy company building the world’s most expansive therapeutic pipeline based on the emerging science of epigenetic engineering. Led by CRISPR pioneer Lei Stanley Qi, PhD, Epic has developed the Gene Expression Modulation System (GEMS) platform, designed to dial gene expression up or down without permanently altering the DNA, and uses Cas12f to deliver genetic therapies that act on the epigenome. The Company's unique epigenetic approach presents enormous therapeutic potential for countless complex diseases. [more information]

Geneius
Geneius Biotechnology enables personalized medicine to transform cancer therapy by targeting multiple cancer driver mutations with T cells that specifically kill cancer cells (not normal cells) and modify the tumor microenvironment across multiple solid and hematologic cancers resulting in a molecular rather than a tissue-based product label for the therapy of cancer. The company uses a proprietary RNA technology that completely revolutionizes the production of personalized T cell products and novel transient technologies that remodel the tumor microenvironment. The company has developed T cell products for first-line, outpatient therapy of cancer by local community oncologists via two 30-minute infusions without toxic chemotherapy, IL-2 or lymphodepletion. [more information]

hC Bioscience, Inc.
hC Bioscience, Inc is an innovator and pioneer of protein editing using gene and context agnostic engineered tRNA. The Company's first in class approach for protein editing advances far beyond genome editing to the direct modification of the proteome, leading to more accurate and efficient gene therapy treatment options. [more information]

Imbria Pharmaceuticals
Imbria Pharmaceuticals, a biotechnology company, developing novel therapies designed to substantially improve the lives of patients with life-altering diseases, with locations in San Diego, CA, and Boston, MA [more information]

Immunai
Developer of a technology intended to provide treatments for oncology and auto-immune disorders. The company's technology combines biology with machine-learning to unravel the immune system, enabling clinicians to comprehensively view and interrogate data and derive novel conclusions on the underlying mechanisms of disease. [more information]

ImmuneSensor
A private, clinical stage therapeutic innate immunity company developing drugs targeting the cGAS-STING pathway for the treatment of cancer and autoimmune diseases. The company was co-founded by Dr. Zhijian “James” Chen of UTSW who won the 2019 Break-through prize and 2018 Lurie prize for the discovery of the cGAS-STING pathway. The company pipeline includes a clinical stage STING agonist, currently in monotherapy and ICI combination trial, with expectations to enter Phase 2 in 2H23. [more information]

Imvax
Imvax’s immunotherapy platform is a multi-step process designed to deliver personalized, whole tumor-derived immunotherapies. [more information]

Indapta Therapeutics
Indapta Therapeutics is a privately held biotechnology company focused on developing and commercializing a proprietary, off-the-shelf, allogeneic FcRγ-deficient natural killer (G-NK) cell therapy to treat multiple types of cancers and address the limitations of currently available autologous T cell therapies. The Company most recently raised over $50 million in Series A financing and commitments co-led by RA Capital Man. [more information]

iOnctura
iOnctura’s drug development programs combine immune-mediated and direct anti-tumor activity to deliver molecules with superior clinical efficacy and safety in oncology. Its lead program, IOA-244, has delivered compelling clinical monotherapy efficacy and safety data in solid and hematologic malignancies and has synergistic potential with standard of care agents across tumor types. iOnctura’s second clinical program, IOA-289, is initiating dosing in a Phase 1b in first-line pancreatic cancer in 3Q22. [more information]

KBio
Creating the new generation of biologics using its plant-based platform that has demonstrated an ability to create potentially better drug candidates at a fraction of the time and cost of conventional platforms. Focused on discovering monoclonal antibodies targeting validated pathways for rare and infectious diseases and, due to the speed and accuracy of its antibody production system, is positioned well to develop fast follower therapies against validated drug targets. [more information]

KisoJi Biotech Inc.
KisoJi is a leading next-generation antibody company developing highly differentiated therapeutic antibodies with novel and/or multi-specific functionality to address difficult targets in oncology and other diseases. [more information]

LENZ
[0910137D]
LENZ Therapeutics is a late-stage clinical company developing innovative ophthalmic pharmaceutical products that improve vision. Their lead program is an aceclidine based eye drop designed to restore the loss of near vision associated with presbyopia. [more information]

MiNA Therapeutics
Leader in RNA activation (RNAa). Technology capable of drugging any protein target to increase natural protein production in patients own cells. Immuno-oncology and rare disease pipeline with 10 clinical assets expected by 2025 and first FDA approval in 2024. Key programs include MTL-CEPBA (ongoing randomized Ph2 in 2L HCC, Ph1/1b in advanced solid tumors resistant to anti-PD1), MTL-STING, monogeneic rare disease programs. $1.5B+ pharma partnerships. [more information]

Minerva Biotechnologies
A clinical stage biopharmaceutical company developing cancer immunotherapies and drugs to target 75% of solid tumors and to prevent cancer metastasis. Minerva has a pipeline that includes next-gen CAR Ts and other modalities. The Company has an ongoing Phase I/II study of huMNC2-CAR44, an autologous CAR T therapy, targeting the tumor-associated form of MUC1 (MUC1*) which is a growth factor receptor that drives growth of an estimated 93% of breast cancers. [more information]

MISSION Therapeutics
Mission Therapeutics is developing a rich pipeline of first-in-class small molecule DUB inhibitors for a number of significant clinical indications. [more information]

Model Medicines
Model Medicines is a new type of software company, combining human expertise and machine learning to accelerate the creation of life-changing Phase II/III ready drug candidates in days rather than decades. [more information]

NodThera Limited
Operator of a clinical-stage biotechnology company intended to develop medicines to treat diseases driven by chronic inflammation. The company is focused on developing a new class of potent and selective NLRP3 inflammasome inhibitors, providing medical practitioners with tools to help patients with various chronic diseases. [more information]

NorthSea Therapeutics
Focused on developing SEFAs for the treatment of NASH and other metabolic disorders. Phase 2b ICONA NASH trial icosabutate showed significant decreases in NASH and fibrotic biomarkers and is scheduled to readout biopsy data in 1Q23. Two additional SEFAs (1024 and 6179) in Phase 1 clinical trials for patients with dyslipidemia and the orphan indication IFALD, respectively. [more information]

Oligon
Oligon Inc. is an emerging biotechnology company developing a novel class of multimodal RNA therapeutics for the treatment of cancer & other complex multigenic diseases. heir proprietary SeekR™ platform is used to digitally engineer and rapidly produce self-delivering therapeutics which target specific tissues with unprecedented precision and accuracy. [more information]

Pipeline Therapeutics
Its flagship program, PIPE-307, has completed a Phase 1 clinical trial in healthy volunteers and will advance into a Phase 2 clinical study in relapsing-remitting MS patients. [more information]

Plexium
Plexium is the premier, next-generation Targeted Protein Degradation (TPD) company seeking to discover a wide range of monovalent target protein degraders that address the limitations of heterobifunctional degraders and cereblon IMiDs. The company is powered by its proprietary drug discovery platform designed to identify novel small molecules that induce selective degradation of drug target proteins through E3 ligase mediated proteasomal degradation. From molecular glues to monovalent degraders, Plexium is advancing a pipeline of novel targeted protein degraders for the treatment of cancer, neurodegeneration, and other diseases. [more information]

Prilenia
Prilenia is a clinical stage biotech company, led by Michael Hayden, MD, PhD., together with a highly experienced team with a track record of success.
Michael is a world-renowned scientist in Huntington Disease research. He is the former President of Global R&D and Chief Scientific Officer at Teva Pharmaceuticals, where he led the development of ~35 new products towards approval in several major markets, predominantly in CNS.
The company has recently raised $68.5M in a Series A financing round to launch [more information]

Prolacta Bioscience
Prolacta Bioscience provides human milk-based nutritional products for premature infants in the neonatal intensive care unit (NICU). They are the world’s leading hospital provider of 100% human milk–based nutritional products, made from 100% donor milk instead of cow milk. [more information]

SparingVision
These novel medicines could form the basis of a suite of new sight-saving treatments with potential applications across many other retinal diseases, regardless of genetic cause. The Company is supported by a strong, internationally renowned team who aim to harness the potential of genomic medicine to deliver new treatments to all ocular disease patients as quickly as possible. SparingVision has raised €60 million to date and its investors include 4BIO Capital, Advent France Biotechnology, Bpifrance, Foundation Fighting Blindness (US), Fondation Voir & Entendre, UPMC Enterprises, Jeito Capital and Ysios Capital. [more information]

Transition Bio
Transition Bio is a microfluidics-driven drug discovery platform company working to establish a one-of-a-kind technology platform using cell imaging and machine learning to revolutionize condensate drug discovery. [more information]

Treos Bio
Develops precision peptide cancer immunotherapies using patient HLA target recognition genetics based on proprietary computational data science. Treos’ lead candidate is PolyPEPI-1018, an off-the-shelf immunotherapy for the treatment of metastatic colorectal cancer currently in a biomarker-based Phase 1b clinical trial. Treos has raised $42 million to date. [more information]

Tune Therapeutics
Tune Therapeutics, Inc. is utilizing the epigenome to treat complex, pervasive diseases that have long eluded treatment. With its versatile and powerful TEMPO epigenomic control platform, Tune’s experienced team is pioneering a new therapeutic modality that can fine-tune any gene network without breaking or permanently rewriting DNA. [more information]

XyloCor Therapeutics
XyloCor Therapeutics is a bio-pharmaceutical company developing gene therapy for people with advanced coronary artery disease. It's lead drug candidate, XC001, is currently in Phase 2 with results reporting out in 2022 and 2023. Promising Phase 1 results were presented earlier this year. [more information]